ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat

Core Insights - Oryzon Genomics has received a "Decision to grant" communication from the European Patent Office for its patent application related to vafidemstat, which is aimed at treating Attention Deficit Hyperactivity Disorder (ADHD) using KDM1A inhibitors [1][2] - The European patent will remain in force until at least 2040, and a corresponding patent has already been granted in Japan for a related application concerning autism spectrum disorder [3][2] - These patent grants enhance Oryzon's intellectual property position and support the commercial potential of vafidemstat across various central nervous system (CNS) indications [4] Patent Developments - The European patent application EP20712563.4 covers methods of treating ADHD with vafidemstat, a compound currently in clinical development [1] - The Japanese patent application JP2022-514201 focuses on treating autism spectrum disorder and is the first in its patent family, with applications pending in other countries [3] - Oryzon's patent portfolio for vafidemstat includes additional families related to aggression, social withdrawal, and borderline personality disorder, with patents granted or allowed in multiple countries [7] Clinical Development - Vafidemstat is an oral, CNS-optimized LSD1 inhibitor that has shown promise in reducing cognitive impairment and neuroinflammation, with positive results in preclinical models and Phase II clinical trials [6][8] - The compound is advancing towards Phase III trials for borderline personality disorder and is also being evaluated for other CNS disorders, including schizophrenia and Kabuki Syndrome [8] - Oryzon has a robust clinical portfolio, with vafidemstat being Phase III-ready and another LSD1 inhibitor, iadademstat, in Phase II for oncology [5]